Want to see FR:DBV full AI Analyst Report?
DBV Stock Chart & Stats
€2.37
€0.07(2.94%)
At close: 4:00 PM EDT
€2.37
€0.07(2.94%)
Day’s Range― - ―
52-Week Range€1.51 - €4.50
Previous CloseN/A
Volume603.12K
Average Volume (3M)1.10M
Market Cap
€698.44M
Enterprise Value€1.09K
Total Cash (Recent Filing)€174.90M
Total Debt (Recent Filing)€21.80M
Price to Earnings (P/E)―
Beta0.47
Next Earnings
Oct 28, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.78
Shares Outstanding314,388,800
10 Day Avg. Volume948,177
30 Day Avg. Volume1,096,552
Financial Highlights & Ratios
PEG Ratio0.53
Price to Book (P/B)3.28
Price to Sales (P/S)0.00
P/FCF Ratio-4.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.17
Revenue Forecast (FY)€3.59M
Bulls Say, Bears Say
Bulls Say
Low LeverageThe low debt burden provides DBV Technologies with greater solvency protection than a highly leveraged biotech and reduces near-term interest and refinancing pressure. Equity-funded assets offer some financial flexibility while the company advances its clinical pipeline.
Focused EPIT PlatformA focused EPIT platform gives DBV Technologies a defined scientific and commercial strategy rather than a broad, unfocused portfolio. Progress with Viaskin Peanut could support product differentiation and create a foundation for future expansion into other immune-mediated conditions.
Improving Free Cash Flow TrendThe reported improvement in free cash flow versus the prior period is a constructive directional signal, suggesting some progress in managing cash usage. Although the absolute deficit remains substantial, continued improvement could extend financial flexibility as development activities proceed.
Bears Say
No Commercial Product RevenueDBV Technologies lacks an established commercial revenue stream, leaving its financial outlook dependent on clinical progress, regulatory approval, and eventual commercialization. This makes revenue visibility weak over the next several quarters and limits internally generated funding for operations.
Deep Operating LossesLarge recurring operating and net losses indicate that the current business is not yet producing economic returns. Persistently negative margins can erode shareholder capital and require substantial future financing before any potential product commercialization improves earnings quality.
Heavy Cash BurnThe magnitude of negative operating and free cash flow shows that DBV Technologies requires significant external funding to sustain its activities. Continued cash consumption can constrain development choices, increase dilution or financing pressure, and weaken resilience if funding conditions deteriorate.
DBV Technologies News
DBV FAQ
What was DBV Technologies’s price range in the past 12 months?
DBV Technologies lowest stock price was €1.51 and its highest was €4.50 in the past 12 months.
What is DBV Technologies’s market cap?
DBV Technologies’s market cap is €698.44M.
When is DBV Technologies’s upcoming earnings report date?
DBV Technologies’s upcoming earnings report date is Oct 28, 2026 which is in 39 days.
How were DBV Technologies’s earnings last quarter?
DBV Technologies released its earnings results on Jul 16, 2026. The company reported -€0.021 earnings per share for the quarter, missing the consensus estimate of -€0.019 by -€0.002.
Is DBV Technologies overvalued?
According to Wall Street analysts DBV Technologies’s price is currently Overvalued.
Does DBV Technologies pay dividends?
DBV Technologies does not currently pay dividends.
What is DBV Technologies’s EPS estimate?
DBV Technologies’s EPS estimate is -0.02.
How many shares outstanding does DBV Technologies have?
DBV Technologies has 314,388,800 shares outstanding.
What happened to DBV Technologies’s price movement after its last earnings report?
DBV Technologies reported an EPS of -€0.021 in its last earnings report, missing expectations of -€0.019. Following the earnings report the stock price went down -7.275%.
Which hedge fund is a major shareholder of DBV Technologies?
Currently, no hedge funds are holding shares in FR:DBV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
DBV Technologies
DBV Technologies S.A. is a clinical-stage biopharmaceutical company focusing on the research and development of epicutaneous immunotherapy products. Its flagship product candidate, Viaskin Peanut, an immunotherapy, has completed Phase III clinical trials and is designed to treat peanut allergies in children aged 4 to 11, as well as adolescents and adults. The company is also advancing Viaskin Milk, which is in Phase I/II clinical trials for Immunoglobulin E (IgE)-mediated cow's milk protein allergy (CMPA). Beyond this, its pipeline includes Viaskin Egg, a preclinical product for hen's egg allergy, and a booster vaccine for Bordetella pertussis. Further early-stage research programs are exploring a vaccine for respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. DBV is collaborating with Nestlé Health Science on MAG1C, a ready-to-use atopy patch test for diagnosing non-IgE mediated CMPA in infants and toddlers. Founded in 2002, DBV Technologies S.A. is headquartered in Montrouge, France.